The Prostate Oncology Program is uniquely positioned to make historic advancements in the prevention, research and treatment of prostate cancer.
A multi-disciplinary team of medical oncologists, radiation oncologists, urologic oncologists, pathologists, radiologists, nurses, social workers, nurse navigators, and researchers, are united in one goal - eradicating prostate cancer. To reach that goal, we have created a prostate cancer research and treatment program of extraordinary quality. It is a place where research discoveries are applied to prevention and treatment, and where compassionate care is given to patients, their families and friends. Cutting-edge clinical trials are a central component of the Prostate Oncology Program.
Rutgers Cancer Institute of New Jersey is a leader in laparoscopic renal procedures and has extensive experience with robotic prostatectomy. The major advantages of robotic prostatectomy include shorter hospital stays, lower blood loss, and faster recovery. Given that robotic surgery is a relatively new technology, surgeon experience is critical for good outcome. Under the leadership of the Urologic Oncology Program, Rutgers Cancer Institute of New Jersey has developed a center of excellence for robotic surgery and its urologic oncologists have performed more than 2,000 robotic prostatectomies.
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, earned several High Performing ratings in the 2023-2024 U.S. News & World Report Best Hospitals survey, including for prostate cancer surgery.
Rutgers Cancer Institute' s Dr. Saum Ghodoussipour discusses the new therapy mitomycin gel, which is the first non-surgical treatment for urothelial cancer.
Project HERO: Health Empowerment & Recovery Outcomes
The purpose of the research is to: determine whether usual care, or a body training program, or a body-mind training program may help improve health and well-being in 166 senior men with a diagnosis of cancer.